Reviewer’s report

**Title:** FGFR4 Gly388Arg polymorphism contributes to prostate cancer risk: A meta-analysis of 2618 cases and 2305 controls

**Version:** 1  **Date:** 2 August 2010

**Reviewer:** Liesel FitzGerald

**Reviewer’s report:**

Xu and colleagues present a meta-analysis of four studies investigating the association between the FGFR4 Gly388Arg polymorphism and prostate cancer risk. This is a well described study using sound statistical methodology. The authors cover the previous literature well and make just conclusions from their findings.

**Minor Essential Revisions:**

I have only two comments that can be addressed at the editor’s discretion. Firstly, whilst the manuscript is generally very well written, there are a few sentences and sections where the English needs to be corrected. In particular, the conclusion paragraph of the abstract, the second paragraph under the Quantitative Synthesis section of the results, and the final concluding paragraph. Also, in the first sentence of the second paragraph of the Discussion, there is a “not” missing from “but not in African Americans (OR=1.15, …etc)”.

Secondly, there is a preprint publication by Xu and colleagues in the European Journal of Cancer that has just been released. This group has done a meta-analysis on the Arg388Gly polymorphism in relation to a number of cancers, including prostate cancer. As you state in the discussion that this is the only meta-analysis done to your knowledge, but this manuscript has only been released, it is up to the editor as to whether you should acknowledge this publication.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests